Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors
Dual Targeting: Iza-bren Shows Promising Early Results Across Solid Tumors

Samantha El Warrak, MBBS, Chinmay Jani, MD

PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety
PALOMA-2: Subcutaneous Amivantamab Plus Lazertinib Delivers MARIPOSA-Level Efficacy with Improved Safety

Akshee Batra, MD, Chinmay Jani, MD

DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC
DLL3-Targeted Antibody-Drug Conjugate Reignites Hope for Relapsed SCLC

Asad Rauf, MD, Chinmay Jani, MD, Aman Chauhan, MD

Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC
Chemotherapy Plus Osimertinib Offers Overall Survival Benefit in EGFR-mutated NSCLC

Daniel Tuerff, MD, Chinmay Jani, MD, Estelamari Rodriguez, MD, MPH

Key NSCLC Trials From WCLC 2025 
Key NSCLC Trials From WCLC 2025 

Balazs Halmos, MD, Rahul Gosain, MD, MBA, Rohit Gosain, MD